Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Spero Therapeutics Inc. is currently managing 3 pending office actions within the Biotechnology & Pharmaceuticals technology area. Each of these 3 pending office actions is assigned to a different person among 3 distinct examiners, resulting in a decentralized prosecution process. The applications are also located in 3 distinct art units, indicating that the company's current intellectual property efforts are spread across different technical focuses within the Biotechnology & Pharmaceuticals field.
TRAN, SUSAN T is listed as the busiest examiner, but she is responsible for 1 pending office action. Because there are 3 distinct examiners and 3 distinct art units for the current workload, there is no opportunity for examiner-specific or unit-specific synergy. Practitioners must handle each of the 3 pending office actions as an isolated case, as the rules and preferences of the various art units will likely vary. This distribution highlights a specialized portfolio where each application represents a unique technical challenge. The 1 pending office action per examiner indicates that no single official has a broad view of the company's current filings across the 3 distinct art units.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting only | 1 (33%) |
| Double-patenting + other | 1 (33%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| TRAN, SUSAN T | 1 | 63.0% | +34.8% |
| YOO, SUN JAE | 1 | 71.2% | +0.3% |
| REYNOLDS, FRED H | 1 | 32.9% | +39.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19554575 | HIGH DOSAGE TEBIPENEM PIVOXIL TABLET FORMULATION | TRAN, SUSAN T | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19554575 | HIGH DOSAGE TEBIPENEM PIVOXIL TABLET FORMULATION | TRAN, SUSAN T | — |
| 18126270 | POLYMYXIN DERIVATIVES AND THEIR USE IN COMBINATION THERAPY TOGETHER WITH DIFFERENT ANTIBIOTICS | REYNOLDS, FRED H | — |
| Art Unit | Apps |
|---|---|
| 1615 | 1 |
| 1621 | 1 |
| 1658 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19554575 | HIGH DOSAGE TEBIPENEM PIVOXIL TABLET FORMULATION | TRAN, SUSAN T | 1615 | §102§103 | Non-Final OA | — | Pending | Mar 02, 2026 |
| 18823147 | TEBIPENEM PIVOXIL CRYSTALLINE FORMS, COMPOSITIONS INCLUDING THE SAME, METHODS OF MANUFACTURE, AND METHODS OF USE | YOO, SUN JAE | 1621 | DP | Non-Final OA | — | Pending | Sep 03, 2024 |
| 18126270 | POLYMYXIN DERIVATIVES AND THEIR USE IN COMBINATION THERAPY TOGETHER WITH DIFFERENT ANTIBIOTICS | REYNOLDS, FRED H | 1658 | §103DP | Final Rejection | — | Pending | Mar 24, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialSpero Therapeutics Inc. has 3 pending office actions as of October 2026, spread across 3 art units and 3 examiners.
Susan T Tran has the most, with 1 of Spero Therapeutics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
